The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | C | Cardiovascular system | |
2 | C09 | Agents acting on the renin-angiotensin system | |
3 | C09A | ACE inhibitors, plain | |
4 | C09AA | ACE inhibitors, plain | |
5 | C09AA01 | Captopril |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
Route | Amount |
---|---|
ORAL - Oral | 50 mg |
Active Ingredient | Description | |
---|---|---|
Captopril |
Captopril is a highly specific, competitive inhibitor of angiotensin-I converting enzyme (ACE inhibitors). Inhibition of ACE results in decreased plasma angiotensin-II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. In patients with hypertension, captopril causes a reduction in supine and erect blood pressure, without inducing any compensatory increase in heart rate, nor water and sodium retention. |
Title | Information Source | Document Type | |
---|---|---|---|
CAPOTEN Tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
EPSITRON Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
NOYADA Oral solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
RILCAPTON Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.